Discover 2,717 paid clinical trials in Ontario. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Filter
1
Filter results
Results: 2,717
VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy
for
Venous Thromboembolism, Urologic Cancer
Location: Ottawa
Sponsor: Ottawa Hospital Research Institute
Sex: All
Age: 18+
Code: NCT05920343
Phase2, Phase3, Recruiting
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer
for
Oropharyngeal Cancer
Location: Sherbrooke, Berlin Corners VT, Burlington VT, Montreal,
Sponsor: Canadian Cancer Trials Group
Sex: All
Age: 18+
Code: NCT05451004
Phase3, Recruiting
DDAVP vs. Exercise in Patients With Mild Hemophilia A
for
Mild Haemophilia A Without Inhibitor
Location: Toronto
Sponsor: The Hospital for Sick Children
Sex: Male
Age: 13 - 21
Code: NCT03136003
Recruiting
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
for
Dravet Syndrome
Location: New Haven CT, New York NY, Philadelphia PA, Ottawa,
Sponsor: Epygenix
Sex: All
Age: 2+
Code: NCT04462770
Phase3, Recruiting
Featured
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
for
Atopic Dermatitis
Location: Quincy MA, Boston MA, New Haven CT, Lebanon NH, Quebec,
Sponsor: AbbVie
Sex: All
Age: 18 - 63
Code: NCT06389136
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
for
Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8,
Location: Saint John, Bath ME, Portland ME, Scarborough ME,
Sponsor: NRG Oncology
Sex: Male
Age: 18+
Code: NCT05946213
Phase3, Recruiting
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation